Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD.
Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF, Porsbjerg C, Knudsen JD, Jensen JU. Corti C, et al. Among authors: jensen bn, jensen ju. Int J Chron Obstruct Pulmon Dis. 2016 Jun 22;11:1381-9. doi: 10.2147/COPD.S104051. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27382274 Free PMC article. Clinical Trial.
Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use.
Schuetz P, Beishuizen A, Broyles M, Ferrer R, Gavazzi G, Gluck EH, González Del Castillo J, Jensen JU, Kanizsai PL, Kwa ALH, Krueger S, Luyt CE, Oppert M, Plebani M, Shlyapnikov SA, Toccafondi G, Townsend J, Welte T, Saeed K. Schuetz P, et al. Among authors: jensen ju. Clin Chem Lab Med. 2019 Aug 27;57(9):1308-1318. doi: 10.1515/cclm-2018-1181. Clin Chem Lab Med. 2019. PMID: 30721141 Free article.
Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial.
Sivapalan P, Jørgensen NR, Mathioudakis AG, Eklöf J, Lapperre T, Ulrik CS, Andreassen HF, Armbruster K, Sivapalan P, Janner J, Godtfredsen N, Weinreich UM, Nielsen TL, Seersholm N, Wilcke T, Schuetz P, Klausen TW, Marså K, Vestbo J, Jensen JU. Sivapalan P, et al. Among authors: jensen ju. Respir Res. 2020 Oct 12;21(1):263. doi: 10.1186/s12931-020-01531-9. Respir Res. 2020. PMID: 33046053 Free PMC article. Clinical Trial.
Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.
Sivapalan P, Rutishauser J, Ulrik CS, Leuppi JD, Pedersen L, Mueller B, Eklöf J, Biering-Sørensen T, Gottlieb V, Armbruster K, Janner J, Moberg M, Lapperre TS, Nielsen TL, Browatzki A, Mathioudakis A, Vestbo J, Schüetz P, Jensen JU. Sivapalan P, et al. Among authors: jensen ju. Respir Res. 2021 May 21;22(1):155. doi: 10.1186/s12931-021-01745-5. Respir Res. 2021. PMID: 34020641 Free PMC article.
Clinical impact of vital sign abnormalities in patients admitted with acute exacerbation of chronic obstructive pulmonary disease: an observational study using continuous wireless monitoring.
Elvekjaer M, Rasmussen SM, Grønbæk KK, Porsbjerg CM, Jensen JU, Haahr-Raunkjær C, Mølgaard J, Søgaard M, Sørensen HBD, Aasvang EK, Meyhoff CS. Elvekjaer M, et al. Among authors: jensen ju. Intern Emerg Med. 2022 Sep;17(6):1689-1698. doi: 10.1007/s11739-022-02988-w. Epub 2022 May 20. Intern Emerg Med. 2022. PMID: 35593967
Core outcome sets, developed collaboratively with patients, can improve the relevance and comparability of clinical trials.
Mathioudakis AG, Khaleva E, Fally M, Williamson PR, Jensen JU, Felton TW, Brightling C, Bush A, Winders T, Linnell J, Ramiconi V, Coleman C, Welte T, Roberts G, Vestbo J. Mathioudakis AG, et al. Among authors: jensen ju. Eur Respir J. 2023 Apr 3;61(4):2202107. doi: 10.1183/13993003.02107-2022. Print 2023 Apr. Eur Respir J. 2023. PMID: 37012082 No abstract available.
The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients.
Jensen JU, Lundgren B, Hein L, Mohr T, Petersen PL, Andersen LH, Lauritsen AO, Hougaard S, Mantoni T, Bømler B, Thornberg KJ, Thormar K, Løken J, Steensen M, Carl P, Petersen JA, Tousi H, Søe-Jensen P, Bestle M, Hestad S, Andersen MH, Fjeldborg P, Larsen KM, Rossau C, Thomsen CB, Ostergaard C, Kjaer J, Grarup J, Lundgren JD. Jensen JU, et al. BMC Infect Dis. 2008 Jul 13;8:91. doi: 10.1186/1471-2334-8-91. BMC Infect Dis. 2008. PMID: 18620598 Free PMC article. Clinical Trial.
185 results